[Form 4] Inmune Bio, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Inmune Bio, Inc. (INMB) reported a one-time repricing of certain outstanding stock options for a company director effective November 18, 2025. The stockholders approved reducing the exercise price of these existing options to $1.50 per share, which matches the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date. Multiple previously granted stock options with higher exercise prices, covering blocks such as 108,000, 35,000, 32,500 and other share amounts, were cancelled and replaced with new options for the same number of underlying common shares at the new $1.50 exercise price. All other terms of the repriced options, including vesting schedules and expiration dates under the company’s 2017, 2019 and 2021 stock incentive plans, remain unchanged.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 15,975 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 15,975 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 19,025 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 19,025 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 32,500 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 32,500 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 12,500 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 12,500 | $0.00 | -- |
Footnotes (1)
- Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
